Sign up to save your podcasts
Or
Share S12 Ep28: Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
S12 Ep28: Ponatinib Monotherapy Maintains MRD Negativity Following TKI/Chemotherapy Treatment in Ph+ ALL: With Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
In today’s episode, supported by Takeda, we had the pleasure of speaking with Ibrahim T. Aldoss, MD, and Elias Jabbour, MD, about the use of ponatinib (Iclusig) monotherapy after combination chemotherapy in patients with newly diagnosed Philadelphia chromosome–positive (Ph)–positive acute lymphoblastic leukemia (ALL). Dr Aldoss is an associate professor in the Division of Leukemia in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. Jabbour is a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.
In our exclusive interview, Drs Aldoss and Jabbour discussed findings from a post hoc subgroup analysis of the phase 3 PhALLCON trial (NCT03589326) that support the use of ponatinib monotherapy following combination treatment with a TKI plus chemotherapy in patients with newly diagnosed Ph-positive ALL, safety considerations when using ponatinib in this patient population, and how findings from this subgroup analysis may affect transplantation rates in this disease.
View all episodes
By OncLive® On Air
4.2
2121 ratings
In today’s episode, supported by Takeda, we had the pleasure of speaking with Ibrahim T. Aldoss, MD, and Elias Jabbour, MD, about the use of ponatinib (Iclusig) monotherapy after combination chemotherapy in patients with newly diagnosed Philadelphia chromosome–positive (Ph)–positive acute lymphoblastic leukemia (ALL). Dr Aldoss is an associate professor in the Division of Leukemia in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. Jabbour is a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston.
In our exclusive interview, Drs Aldoss and Jabbour discussed findings from a post hoc subgroup analysis of the phase 3 PhALLCON trial (NCT03589326) that support the use of ponatinib monotherapy following combination treatment with a TKI plus chemotherapy in patients with newly diagnosed Ph-positive ALL, safety considerations when using ponatinib in this patient population, and how findings from this subgroup analysis may affect transplantation rates in this disease.
More shows like OncLive® On Air
View all
Wait Wait... Don't Tell Me!
38,649 Listeners
Marketplace Morning Report
890 Listeners
Marketplace
8,649 Listeners
Research To Practice | Oncology Videos
113 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
10 Listeners
JAMA Clinical Reviews
493 Listeners
ASCO Daily News
58 Listeners
The Curbsiders Internal Medicine Podcast
3,332 Listeners
OncoPharm
185 Listeners
ASCO Guidelines
43 Listeners
Lung Cancer Considered
26 Listeners
Oncology Today with Dr Neil Love
52 Listeners
Two Onc Docs
169 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
39 Listeners
NEJM AI Grand Rounds
51 Listeners